tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplant. Proc. pmid:8962225
Scott-Douglas N et al. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. 1996 Transplant. Proc. pmid:8962226
Kliem V et al. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. 1996 Transplant. Proc. pmid:8962227
Becker G et al. Tacrolimus (FK 506) therapy in simultaneous pancreas kidney transplantation. 1996 Transplant. Proc. pmid:8962228
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Guckelberger O et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? 1996 Transplant. Proc. pmid:8962230
Braun F et al. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. 1996 Transplant. Proc. pmid:8962231
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Golling M et al. Tacrolimus reduction improves glucose metabolism and insulin secretion after liver transplantation. 1996 Transplant. Proc. pmid:8962234
Platz KP et al. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients. 1996 Transplant. Proc. pmid:8962235
Mollison KW et al. Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat. 1996 Transplant. Proc. pmid:8962236
Yokoyama I et al. Decreased Fas antigen expression of cultured hepatocytes with FK 506. 1996 Transplant. Proc. pmid:8962237
Mueller AR et al. Long-term follow-up in hepatitis C patients with respect to immunosuppression. 1996 Transplant. Proc. pmid:8962255
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Kawasaki M et al. [Immunosuppression and the problems in partial liver transplantation]. 1995 Nihon Rinsho Meneki Gakkai Kaishi pmid:8963785
Teraoka S et al. [Present status and problems in clinical application of tacrolimus(FK506)]. 1995 Nihon Rinsho Meneki Gakkai Kaishi pmid:8963787
Guérette B et al. Increased interferon-gamma mRNA expression following alloincompatible myoblast transplantation is inhibited by FK506. 1996 Muscle Nerve pmid:8965835
Sharkey J et al. Tacrolimus (FK506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats. 1996 Stroke pmid:8969794
Hedayat S et al. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. 1996 J Biopharm Stat pmid:8969977
Taler SJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. 1996 Transplantation pmid:8970613
Hisanaga Y et al. Implication of nitric oxide synthase activity in the genesis of water immersion stress-induced gastric lesions in rats: the protective effects of FK506. 1996 Aliment. Pharmacol. Ther. pmid:8971291
Corey HE et al. Improved renal allograft survival in children treated with FK 506 (tacrolimus) rescue therapy. 1996 Pediatr. Nephrol. pmid:8971888
Morris RE Transplantation. Beware: shifting paradigms ahead. 1996 Dec 21-28 Lancet pmid:8973504
James DG A new immunosuppressant: tacrolimus. 1996 Postgrad Med J pmid:8977938
Blecher O et al. A novel plant peptidyl-prolyl-cis-trans-isomerase (PPIase): cDNA cloning, structural analysis, enzymatic activity and expression. 1996 Plant Mol. Biol. pmid:8980498
Odom A et al. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. 1997 Antimicrob. Agents Chemother. pmid:8980772
Nichterlein T et al. Effects of FK-506 on the course of murine salmonellosis. 1996 J Chemother pmid:8981186
Redmon JB et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. 1996 J. Clin. Invest. pmid:8981925
Sempuku T et al. Osteogenic potential of allogeneic rat marrow cells in porous hydroxyapatite ceramics: a histological study. 1996 J. Orthop. Res. pmid:8982133
High KP and Washburn RG Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin). 1997 J. Infect. Dis. pmid:8985226
Yoshikai Y et al. Clonal expansion of superantigen-reactive T cells is resistant to FK506 in mice with AIDS. 1997 J. Virol. pmid:8985410
pmid:8986461
Shapiro R et al. Tacrolimus in pediatric renal transplantation. 1996 Transplantation pmid:8990356
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
Rambusch EG and Manns MP [Therapy of autoimmune hepatitis]. 1996 Dtsch. Med. Wochenschr. pmid:8998922
Ericzon BG et al. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. 1997 Transplantation pmid:9000664
Kelly PA et al. Ciprofloxacin does not block the antiproliferative effect of tacrolimus. 1997 Transplantation pmid:9000686
Nair SC et al. Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. 1997 Mol. Cell. Biol. pmid:9001212
Pirenne J et al. Donor-specific unmodified bone marrow transfusion does not facilitate intestinal engraftment after bowel transplantation in a porcine model. 1997 Surgery pmid:9001555
Felldin M et al. Rescue therapy with tacrolimus (FK 506) in renal transplant recipients--a Scandinavian multicenter analysis. 1997 Transpl. Int. pmid:9002146
Becker G et al. Rescue therapy with tacrolimus in simultaneous pancreas/kidney transplantation. 1997 Transpl. Int. pmid:9002152
Matsui A et al. Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. 1996 Acta Paediatr Jpn pmid:9002314
DeCenzo MT et al. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes. 1996 Protein Eng. pmid:9005438
Noguchi N et al. Cyclic ADP-ribose binds to FK506-binding protein 12.6 to release Ca2+ from islet microsomes. 1997 J. Biol. Chem. pmid:9013543
Ishizuka T et al. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. 1997 Biochem. Biophys. Res. Commun. pmid:9016789
Richardson D et al. The successful conversion to Tacrolimus (FK506) of a renal transplant recipient with cyclosporin-induced haemolytic-uraemic syndrome. 1996 Nephrol. Dial. Transplant. pmid:9017633
Sano Y et al. Effect of a single injection of high-dose FK506 on lung transplantation in rats. 1996 Surg. Today pmid:9017963
Villalba L and Adams EM Update on therapy for refractory dermatomyositis and polymyositis. 1996 Curr Opin Rheumatol pmid:9018458
Jordan ML et al. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. 1997 Transplantation pmid:9020321
Mazariegos GV et al. Weaning of immunosuppression in liver transplant recipients. 1997 Transplantation pmid:9020325
Marks WH et al. Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes. 1997 Transplantation pmid:9020333
[Tacrolimus--a new perspective in kidney transplantation]. 1996 Urologe A pmid:9022401
Aiko S et al. Effects of cyclosporine or FK506 in chronic colitis. 1997 J. Pharmacol. Exp. Ther. pmid:9023326
Budde K et al. Differing proteinuria control with cyclosporin and tacrolimus. 1997 Lancet pmid:9024386
Lo Russo A et al. Cyclosporin A potentiates receptor-activated [Ca2+]c increase. 1997 Jan-May J. Recept. Signal Transduct. Res. pmid:9029487
Iwasaki K et al. Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid. 1996 Res. Commun. Mol. Pathol. Pharmacol. pmid:9029671
Alak AM et al. A highly sensitive enzyme-linked immunosorbent assay for the determination of tacrolimus in atopic dermatitis patients. 1997 Ther Drug Monit pmid:9029754
Padhi ID et al. Interaction between tacrolimus and erythromycin. 1997 Ther Drug Monit pmid:9029762
Markus PM et al. Allogeneic hepatocyte transplantation using FK 506. 1997 Jan-Feb Cell Transplant pmid:9040958
Tsuchida Y et al. Limb allografts in rats treated with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies. 1997 J Reconstr Microsurg pmid:9044184
Wang W et al. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. 1997 Immunity pmid:9047238
Steiner JP et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9050897
Seidel ER and Ragan VL Inhibition by rapamycin of ornithine decarboxylase and epithelial cell proliferation in intestinal IEC-6 cells in culture. 1997 Br. J. Pharmacol. pmid:9051292
Bagnis C et al. Comparative acute nephrotoxicity of FK-506 and ciclosporin in an isolated in situ autoperfused rat kidney model. 1997 Am. J. Nephrol. pmid:9057948
Ivery MT and Weiler L Modeling the interaction between FK506 and FKBP12: a mechanism for formation of the calcineurin inhibitory complex. 1997 Bioorg. Med. Chem. pmid:9061187
Garcia-Morales R et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. 1997 J. Clin. Invest. pmid:9062371
Göthel SF et al. An internal FK506-binding domain is the catalytic core of the prolyl isomerase activity associated with the Bacillus subtilis trigger factor. 1997 Eur. J. Biochem. pmid:9063446
Motamedi H et al. Structural organization of a multifunctional polyketide synthase involved in the biosynthesis of the macrolide immunosuppressant FK506. 1997 Eur. J. Biochem. pmid:9063448
Guckelberger O et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. 1997 Clin Transplant pmid:9067697
Singh N et al. Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus. 1997 Clin Transplant pmid:9067698
Victor RG et al. Mechanism of Ca(2+)-dependent inactivation of L-type Ca2+ channels in GH3 cells: direct evidence against dephosphorylation by calcineurin. 1997 J. Membr. Biol. pmid:9070464
Grobecker HF et al. Cyclosporine A-induced hypertension in SHR and WKY: role of the sympatho-adrenal system. 1995 Clin Exp Pharmacol Physiol Suppl pmid:9072458
Guo Z et al. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. 1997 Transplantation pmid:9075844
Ciancio G et al. Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506. 1997 Transplantation pmid:9075856
Mirza DF et al. Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression. 1997 Lancet pmid:9078209
Yoshikawa H et al. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. 1997 J. Autoimmun. pmid:9080295
de Paulis A et al. Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. 1997 Arthritis Rheum. pmid:9082935
Ohashi Y et al. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. 1997 Bone Marrow Transplant. pmid:9085743
Oz HS and Hughes WT Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. 1997 J. Infect. Dis. pmid:9086147
Wagner K et al. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 1997 J. Heart Lung Transplant. pmid:9087870
Yasutomi M et al. Evaluation of tetrahydropyranyladriamycin as an immunosuppressant in concordant xenotransplantation. 1997 J. Heart Lung Transplant. pmid:9087871
Morrissey PE et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. 1997 Transplantation pmid:9089224
Kiuchi T et al. A hepatic graft tuberculosis transmitted from a living-related donor. 1997 Transplantation pmid:9089234
Krämer BK and Schweda F Differing proteinuria control with cyclosporin and tacrolimus. 1997 Lancet pmid:9093272
Maurer M et al. Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. 1997 Am. J. Pathol. pmid:9094998
Steiner JP et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. 1997 Nat. Med. pmid:9095176
Mori A et al. Enhanced production and gene expression of IL-5 in bronchial asthma. Possible management of atopic diseases with IL-5 specific gene transcription inhibitor. 1996 Adv. Exp. Med. Biol. pmid:9095279
Blau CA et al. A proliferation switch for genetically modified cells. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9096348
Bowman AR et al. The role of testosterone in cyclosporine-induced osteopenia. 1997 J. Bone Miner. Res. pmid:9101372
Taylor P et al. Conformational polymorphism in peptidic and nonpeptidic drug molecules. 1996 Biopolymers pmid:9101762
Guérette B et al. Inflammatory damage following first-generation replication-defective adenovirus controlled by anti-LFA-1. 1997 J. Leukoc. Biol. pmid:9103242
Mori A et al. IL-2-induced IL-5 synthesis, but not proliferation, of human CD4+ T cells is suppressed by FK506. 1997 J. Immunol. pmid:9103428
Hess DA et al. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation. 1997 J. Pharmacol. Exp. Ther. pmid:9103542
Kawamura N et al. Extremely high serum level of IgE during immunosuppressive therapy: paradoxical effect of cyclosporine A and tacrolimus. 1997 Int. Arch. Allergy Immunol. pmid:9104801
Beals CR et al. Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. 1997 Genes Dev. pmid:9106655
Lee JW et al. Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study. 1997 Ther Drug Monit pmid:9108651
Holt DW and Johnston A Tacrolimus quality assessment. 1997 Ther Drug Monit pmid:9108659
Pirsch JD et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9112351
Hikita N et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. 1997 Invest. Ophthalmol. Vis. Sci. pmid:9112986